DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

120
SECTION I
GENERAL PRINCIPLES
multidrug resistance-associated protein 2 (MRP2/ABCC2).
J Biol Chem, 2002, 277:6497–6503.
Sassi Y, Lipskaia L, Vandecasteele G, et al. Multidrug resistanceassociated
protein 4 regulates cAMP-dependent signaling
pathways and controls human and rat SMC proliferation. J Clin
Invest, 2008, 118:2747–2757.
Schinkel AH, Smit JJ, van Tellingen O. Disruption of the mouse
mdrla P-glycoprotein gene leads to a deficiency in the blood–
brain barrier and to increased sensitivity to drugs. Cell, 1994,
77:491–502.
Schuetz JD, Connelly MC, Sun D. MRP4: A previously
unidentified factor in resistance to nucleoside-based antiviral
drugs. Nature Med, 1999, 5:1048–1051.
Search Collaborative Group. SLC01B1 variants and statininduced
myopathy—a genomewide study. N Engl J Med,
2008, 359:789–799.
Sekine T, Cha SH, Tsuda M, et al. Identification of multispecific
organic anion transporter 2 expressed predominantly in the
liver. FEBS Lett, 1998, 429:179–182.
Sekine T, Watanabe N, Hosoyamada M, et al. Expression cloning
and characterization of a novel multispecific organic anion
transporter. J Biol Chem, 1997, 272:18526–18529.
Schousboe A, Sarup A, Larsson OM, White HS. GABA
transporters as drug targets for modulation of GABAergic
activity. Biochem Pharmacol, 2004, 68:1557–1563.
Shigeri Y, Seal RP, Shimamoto K. Molecular pharmacology of
glutamate transporters, EAATs and VGLUTs. Brain Res Rev,
2004, 45:250–265.
Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of
drug clearance and tissue distribution. Eur J Pharm Sci, 2006,
27:425-446.
Shitara Y, Itoh T, Sato H, et al. Inhibition of transporter-mediated
hepatic uptake as a mechanism for drug–drug interaction
between cerivastatin and cyclosporin A. J Pharmacol Exp
Ther, 2003, 304:610–616.
Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug
interaction in the hepatobiliary and renal transport of drugs.
Annu Rev Pharmacol Toxicol, 2005, 45:689–723.
Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation
predicts function of variants of the human organic cation
transporter, OCT1. Proc Natl Acad Sci USA, 2003, 100:
5902–5907.
Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation
in the organic cation transporter 1 (OCT1) on metformin
action. J Clin Invest, 2007, 117:1422–1431.
Simonson GD, Vincent AC, Roberg KJ, et al. Molecular cloning
and characterization of a novel liver-specific transport protein.
J Cell Sci, 1994, 107:1065–1072.
Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic
cation transporter 2 influence the disposition of metformin.
Nature Pub Group, 2008, 84:559–562.
Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG.
Molecular biology, pharmacology and functional role of the
plasma membrane dopamine transporter. CNS Neurol Disord
Drug Targets, 2006, 5:45–56.
Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and
regulation of the cloned organic anion transporters.
Xenobiotica, 2008, 38:889–935.
Stieger B, Fattinger K, Madon J, et al. Drug- and estrogeninduced
cholestasis through inhibition of the hepatocellular
bile salt export pump (BSEP) of rat liver. Gastroenterology,
2000, 118:422–430.
Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liverspecific
ABC transporter is mutated in progressive familial
intrahepatic cholestasis. Nat Genet, 1998, 20:233–238.
Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters
in the CNS. Adv Drug Deliv Rev, 2003, 55:83–105.
Sweet DH, Wolff NA, Pritchard JB. Expression cloning and
characterization of ROAT1: The basolateral organic anion
transporter in rat kidney. J Biol Chem, 1997, 272:30088–30095.
Szakacs G, Paterson J, Ludwig J, et al. Targeting multidrug
resistance in cancer. Nature Rev, 2006, 5:219–234.
Takeda M, Tojo A, Sekine T, et al. Role of organic anion
transporter 1 (OAT1) in cephaloridine (CER)-induced
nephrotoxicity. Kidney Int, 1999, 56:2128–2136.
Takenaka K, Morgan JA, Scheffer GL, et al. Substrate overlap
between MRP4 and ABCG2/BCRP affects purine analogue
drug cytotoxicity and tissue distribution. Cancer Res, 2007,
67:6965–6972.
Tamai I, Ohashi R, Nezu J, et al. Molecular and functional
identification of sodium ion–dependent, high affinity human
carnitine transporter OCTN2. J Biol Chem, 1998, 273:20378–
20382.
Tamai I, Yabuuchi H, Nezu J, et al. Cloning and characterization
of a novel human pH-dependent organic cation transporter,
OCTN1. FEBS Lett, 1997, 419:107–111.
Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of
MATE1 and MATE2-K, human multidrug and toxin
extrusions/H + -organic cation antiporters. Biochem Pharmacol,
2007, 74:359–371.
Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in
OATP-C: Identification of multiple allelic variants associated
with altered transport activity among European- and African-
Americans. J Biol Chem, 2001, 276: 35669–35675.
Torres G, Amara S. Glutamate and monoamine transporters:
New visions of form and function. Curr Opin Neurobiol, 2007,
17:304–312.
Toyoda Y, Hagiya Y, Adachi T, et al. MRP class of human ATP
binding cassette (ABC) transporters: Historical background
and new research directions. Xenobiotica, 2008, 38:833–
862.
Treiber A, Schneiter R, Häusler S, et al. Bosentan is a substrate
of human OATP1B1 and OATP1B3: inhibition of hepatic
uptake as the common mechanism of its interactions with
cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos,
2007, 35:1400–1407.
Turner JG, Gump JL, Zhang C, et al. ABCG2 expression,
function, and promoter methylation in human multiple
myeloma. Blood, 2006, 108:3881–3889.
Uchiumi T, Kohno K, Tanimura H, et al. Enhanced expression of
the human multidrug resistance 1 gene in response to UV light
irradiation. Cell Growth Differ, 1993, 4:147–157.
Uhl GR. Dopamine transporter: basic science and human variation
of a key molecule for dopaminergic function, locomotion, and
parkinsonism. Mov Disord, 2003, 18:S71–S80.
Urakami Y, Akazawa M, Saito H, et al. cDNA cloning, functional
characterization, and tissue distribution of an alternatively
spliced variant of organic cation transporter hOCT2
predominantly expressed in the human kidney. J Am Soc
Nephrol, 2002, 13:1703–1710.